Dimitris Tsoukalas

Dr. Dimitris Tsoukalas

European Institute of Nutritional Medicine
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2018 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
George Mihai NitulescuGeorge Mihai Nitulescu
George Mihai Nitulescu
MVMaryna Van De Venter
Maryna Van De Venter
GNGeorgiana Nitulescu
Georgiana Nitulescu
AUAnca Ungurianu
Anca Ungurianu
PJPetras Juzenas
Petras Juzenas
Denisa MarginaDenisa Margina
Denisa Margina
Protein kinase B (Akt), similar to many other protein kinases, is at the crossroads of cell death and survival, playing a pivotal role in multiple interconnected cell signaling mechanisms implicated in cell metabolism, growth and division, apoptosis suppression and angiogenesis. Akt protein kinase displays important metabolic effects, among which are glucose uptake in muscle and fat cells or the suppression of neuronal cell death. Disruptions in the Akt‑regulated pathways are associated with cancer, diabetes, cardiovascular and neurological diseases. The regulation of the Akt signaling pathway renders Akt a valuable therapeutic target. The discovery process of Akt inhibitors using various strategies has led to the identification of inhibitors with great selectivity, low side‑effects and toxicity. The usefulness of Akt emerges beyond cancer therapy and extends to other major diseases, such as diabetes, heart diseases, or neurodegeneration. This review presents key features of Akt structure and functions, and presents the progress of Akt inhibitors in regards to drug development, and their preclinical and clinical activity in regards to therapeutic efficacy and safety for patients.

1 December 2017 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
Chiara CostaChiara Costa
Chiara Costa
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
CHARALAMPOS MAMOULAKISCHARALAMPOS MAMOULAKIS
CHARALAMPOS MAMOULAKIS
MTMichele Teodoro
Michele Teodoro
GBGiusi Briguglio
Giusi Briguglio
Concettina FengaConcettina Fenga
Concettina Fenga

8 May 2019 in Comprehensive Reviews in Food Science and Food Safety
Verified
Journal Article
Open access
PDF file
AZAnca Zanfirescu
Anca Zanfirescu
AUAnca Ungurianu
Anca Ungurianu
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
George Mihai NitulescuGeorge Mihai Nitulescu
George Mihai Nitulescu
DKDemetrios Kouretas
Demetrios Kouretas
Denisa MarginaDenisa Margina
Denisa Margina
Monosodium glutamate (MSG) is an umami substance widely used as flavor enhancer. Although it is generally recognized as being safe by food safety regulatory agencies, several studies have questioned its long‐term safety. The purpose of this review was to survey the available literature on preclinical studies and clinical trials regarding the alleged adverse effects of MSG. Here, we aim to provide a comprehensive overview of the reported possible risks that may potentially arise following chronic exposure. Preclinical studies have associated MSG administration with cardiotoxicity, hepatotoxicity, neurotoxicity, low‐grade inflammation, metabolic disarray, and premalignant alterations, along with behavioral changes. However, in reviewing the available literature, we detected several methodological flaws, which led us to conclude that these studies have limited relevance for extrapolation to dietary human intake of MSG risk exposure. Clinical trials have focused mainly on MSG effects on food intake and energy expenditure. Besides its well‐known impact on food palatability, MSG enhances salivary secretion and interferes with carbohydrate metabolism, while the impact on satiety and post‐meal recovery of hunger varied in relation to meal composition. Reports on MSG hypersensitivity or links of its use to increased pain sensitivity and atopic dermatitis were found to have little supporting evidence. Many of the reported negative health effects of MSG have little relevance for chronic human exposure and are poorly informative as they are based on excessive dosing that does not meet with levels normally consumed in food products. We conclude that further clinical and epidemiological studies are needed, with an appropriate design, accounting for both added and naturally occurring dietary MSG.

27 March 2020 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
Anca Oana DoceaAnca Oana Docea
Anca Oana Docea
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
DADana Albulescu
Dana Albulescu
OCOana Cristea
Oana Cristea
OZOvidiu Zlatian
Ovidiu Zlatian
Daniela CalinaDaniela Calina
Daniela Calina
The new outbreak of coronavirus from December 2019 has brought attention to an old viral enemy and has raised concerns as to the ability of current protection measures and the healthcare system to handle such a threat. It has been known since the 1960s that coronaviruses can cause respiratory infections in humans; however, their epidemic potential was understood only during the past two decades. In the present review, we address current knowledge on coronaviruses from a short history to epidemiology, pathogenesis, clinical manifestation of the disease, as well as treatment and prevention strategies. Although a great amount of research and efforts have been made worldwide to prevent further outbreaks of coronavirus‑associated disease, the spread and lethality of the 2019 outbreak (COVID‑19) is proving to be higher than previous epidemics on account of international travel density and immune naivety of the population. Only strong, joint and coordinated efforts of worldwide healthcare systems, researchers, and pharmaceutical companies and receptive national leaders will succeed in suppressing an outbreak of this scale.

Denisa MarginaDenisa Margina
Denisa Margina
AUAnca Ungurianu
Anca Ungurianu
NPNicoleta Carmen Purdel
Nicoleta Carmen Purdel
Dimitris TsoukalasDimitris Tsoukalas
Dimitris Tsoukalas
Evangelia SarandiEvangelia Sarandi
Evangelia Sarandi
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
The lifestyle adopted by most people in Western societies has an important impact on the propensity to metabolic disorders (e.g., diabetes, cancer, cardiovascular disease, neurodegenerative diseases). This is often accompanied by chronic low-grade inflammation, driven by the activation of various molecular pathways such as STAT3 (signal transducer and activator of transcription 3), IKK (IκB kinase), MMP9 (matrix metallopeptidase 9), MAPK (mitogen-activated protein kinases), COX2 (cyclooxigenase 2), and NF-Kβ (nuclear factor kappa-light-chain-enhancer of activated B cells). Multiple intervention studies have demonstrated that lifestyle changes can lead to reduced inflammation and improved health. This can be linked to the concept of real-life risk simulation, since humans are continuously exposed to dietary factors in small doses and complex combinations (e.g., polyphenols, fibers, polyunsaturated fatty acids, etc.). Inflammation biomarkers improve in patients who consume a certain amount of fiber per day; some even losing weight. Fasting in combination with calorie restriction modulates molecular mechanisms such as m-TOR, FOXO, NRF2, AMPK, and sirtuins, ultimately leads to significantly reduced inflammatory marker levels, as well as improved metabolic markers. Moving toward healthier dietary habits at the individual level and in publicly-funded institutions, such as schools or hospitals, could help improving public health, reducing healthcare costs and improving community resilience to epidemics (such as COVID-19), which predominantly affects individuals with metabolic diseases.

16 April 2020 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
MGMarina Goumenou
Marina Goumenou
DSDimosthenis Sarigiannis
Dimosthenis Sarigiannis
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
OAOurania Anesti
Ourania Anesti
Anca Oana DoceaAnca Oana Docea
Anca Oana Docea
Daniela CalinaDaniela Calina
Daniela Calina
Italy is currently one of the countries seriously affected by the COVID‑19 pandemic. As per 10 April 2020, 147,577 people were found positive in a total of 906,864 tests performed and 18,849 people lost their lives. Among all cases, 70.2% of positive, and 79.4% of deaths occurred in the provinces of Northern Italy (Lombardi, Emilia Romagna, Veneto and Piemonte), where the outbreak first started. Originally, it was considered that the high number of positive cases and deaths in Italy resulted from COVID‑19 initially coming to Italy from China, its presumed country of origin. However, an analysis of the factors that played a role in the extent of this outbreak is needed. Evaluating which factors could be specific for a country and which might contribute the most is nevertheless complex, with accompanying high uncertainty. The purpose of this work is to discuss some of the possible contributing factors and their possible role in the relatively high infection and death rates in Northern Italy compared to other areas and countries.